Clinical trial · Observational
A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.
NCT04552535CI-TRIAL-00055861completedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Non-small Cell Lung Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Second line (2L) afatinib | Drug | — | UNRESOLVED |
| Second line chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Second line (2L) afatinib
- description
- Second line (2L) afatinib treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
- interventionNames
- Drug: Second line (2L) afatinib
- label
- Second line (2L) chemotherapy
- description
- Second line (2L) chemotherapy treated following discontinuation of pembrolizumab in combination with platinum-based doublet chemotherapy (first line (1L))
- interventionNames
- Drug: Second line chemotherapy
Primary outcomes (4)
- measure
- Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment
- timeFrame
- From the start of second-line treatment until discontinuation of second-line treatment, up to 12.3 months for afatinib treated and up to 7.5 months for chemotherapy treated patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of squamous or mixed histology non-small cell lung cancer * Treated with pembrolizumab in combination with platinum-based chemotherapy as initial therapy for advanced or metastatic disease (stage IIIB or IV) * First cycle of pembrolizumab received after 06/01/2018 * Permanently discontinued 1L pembrolizumab treatment * Initiated second-line treatment at least 3 months prior to the date of data collection, with either : * Afatinib * Any chemotherapy * Age ≥ 18 years Exclusion Criteria: -Received pembrolizumab in combination with platinum-based chemotherapy as part of an interventional clinical trial
References
Publications (0)
Data not yet available
No reference posted for this study.